the Efficacy and Safety of Etanercept （Yi Sai Pu) in Chinese Patients With Moderate-to-Severe Psoriasis
NCT ID: NCT04912401
Last Updated: 2024-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2020-12-04
2025-12-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Etanercept in Patients With Psoriasis
NCT02258282
Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis
NCT00333034
Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis
NCT00111449
Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept
NCT00581165
Study of Etanercept in the Treatment of Psoriasis in Adult Subjects
NCT00121615
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Having severe infections, including hepatitis, HIV and tuberculosis
3. No live vaccines 12 weeks before enrollment, through the study and 1 year after the last dose of Etanercept
4. Having significant allergies to biological agents
5. Having the previous experience of biologics
6. Having a history of malignancy
7. Having contradictions to Etanercept
8. Refusal of contraception
9. Having serious or unstable/uncontrolled illnesses
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiaoyong Man
Principal Investigator, Head of Dermatology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
First Affiliated Hospital, Zhejiang Medical University
Hangzhou, , China
Hang Zhou First People's Hospital
Hangzhou, , China
Hang Zhou Third People's Hospital
Hangzhou, , China
Hospital of dermatology of Xiaoshan
Hangzhou, , China
Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University
Hangzhou, , China
the People Hospital of Zhejiang Province
Hangzhou, , China
Xiaoshan Hospital
Hangzhou, , China
Yuhang Fifth People's Hospital
Hangzhou, , China
Zhejiang Hospital of Traditional Chinese Medicine
Hangzhou, , China
Changxing Dermatology Hospital prevention and Treatment
Huzhou, , China
Chinese 72 Hospital
Huzhou, , China
Hospital of dermatology of Zhejiang Province
Huzhou, , China
Huzhou Central Hospital
Huzhou, , China
Huzhou First Hospital
Huzhou, , China
the People Hospital of Changxing
Huzhou, , China
Jiaxing First Hospital
Jiaxing, , China
Rongjun Hospital of Zhejiang Province
Jiaxing, , China
Tongxiang Dermatology Hospital prevention and Treatment
Jiaxing, , China
Hospital of dermatology of Yiwu
Jinhua, , China
Jinhua Central Hospital
Jinhua, , China
Jinhua Fifth Hospital
Jinhua, , China
the People Hospital of Dongyang
Jinhua, , China
Lishui Central Hospital
Lishui, , China
the People Hospital of Lishui
Lishui, , China
Ningbo Chinese Medical Hospital
Ningbo, , China
Ningbo First Hospital
Ningbo, , China
Ningbo Sixth Hospital
Ningbo, , China
Quzhou Chinese Medical Hospital
Quzhou, , China
the People Hospital of Quzhou
Quzhou, , China
Shangyu of Chinese Medical Hospital
Shaoxing, , China
Shaoxing Central Hospital
Shaoxing, , China
Shaoxing Third Hospital
Shaoxing, , China
the People Hospital of Shaoxing
Shaoxing, , China
Taizhou Central Hospital
Taizhou, , China
Wenling Chinese Medical Hospital
Taizhou, , China
the First Affiliated Hospital of Wenzhou medical university
Wenzhou, , China
the People Hospital of Cangnan
Wenzhou, , China
Wenzhou Chinese Medical Hospital
Wenzhou, , China
Wenzhou Combinational Hospital of Chinese and Western Medicine
Wenzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-915
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.